Patents by Inventor Torsten Hoffmann

Torsten Hoffmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20080275021
    Abstract: The invention relates to pyrrolidine derivatives of formula wherein R1, R2, R3, n, and o are defined in the specification and to pharmaceutically active acid-addition salts thereof. Compounds of formula I have a high affinity simultaneously to both the NK1 and the NK3 receptors (dual NK1/NK3 receptor antagonists), useful in the treatment of schizophrenia.
    Type: Application
    Filed: April 14, 2008
    Publication date: November 6, 2008
    Inventors: Caterina Bissantz, Torsten Hoffmann, Philippe Jablonski, Henner Knust, Mathias Nettekoven, Hasane Ratni, Xihan Wu
  • Publication number: 20080267912
    Abstract: Compounds of formula (I), combinations and uses thereof for disease therapy, or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein: A represents and B, R1, R2, R3, R4, R5, R6 and Z are as defined throughout the description and the claims.
    Type: Application
    Filed: April 18, 2008
    Publication date: October 30, 2008
    Applicant: PROBIODRUG AG
    Inventors: Mirko Buchholz, Ulrich Heiser, Torsten Hoffmann, Livia Boehme
  • Publication number: 20080200567
    Abstract: A transgenic non-human animal, in particular a transgenic mouse, encoding Qpct proteins which have been implicated in Qpct-related diseases. Also disclosed are cells and cell lines comprising transgenes encoding for Qpct. Further disclosed are methods and compositions for evaluating agents that affect Qpct, for use in compositions for the treatment of Qpct-related diseases.
    Type: Application
    Filed: January 18, 2008
    Publication date: August 21, 2008
    Applicant: PROBIODRUG AG
    Inventors: Stephan Schilling, Holger Cynis, Torsten Hoffmann, Hans-Ulrich Demuth, Michael Wermann, Katrin Schulz
  • Patent number: 7381537
    Abstract: The present invention provides novel physiological substrates of mammalian glutaminyl cyclase (QC, EC 2.3.2.5), new effectors of QC, methods for screeing for such effectors, and the use of such effectors and pharmaceutical compositions comprising such effectors for the treatment of conditions that can be treated by modulation of QC-activity. Preferred compositions additionally comprise inhibitors of DP IV or DP IV-like enzymes for the treatment or alleviation of conditions that can be treated by modulation of QC- and DP IV-activity.
    Type: Grant
    Filed: May 5, 2004
    Date of Patent: June 3, 2008
    Assignee: Probiodrug AG
    Inventors: Hans-Ulrich Demuth, Torsten Hoffmann, Andre J. Niestroj, Stephan Schilling, Ulrich Heiser
  • Patent number: 7368421
    Abstract: The present invention provides a new use of DP IV-inhibitors. The compounds of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms, are useful in treating conditions mediated by DP IV or DP IV-like enzymes, such as immune, autoimmune or central nervous system disorder selected from the group consisting of strokes, tumors, ischemia, Parkinson's disease and migraines. In a more preferred embodiment, the compounds of the present invention are useful for the treatment of multiple sclerosis.
    Type: Grant
    Filed: April 19, 2002
    Date of Patent: May 6, 2008
    Assignee: Probiodrug AG
    Inventors: Hans-Ulrich Demuth, Torsten Hoffmann, Konrad Glund, Ulrich Heiser, Stephan von Hoersten
  • Patent number: 7368576
    Abstract: The present invention provides new uses of DPIV-inhibitors of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms, for treating conditions mediated by DPIV or DPIV-like enzymes, such as cancer and tumors. In a more preferred embodiment, the compounds of the present invention are useful for the treatment of metastasis and tumor colonization.
    Type: Grant
    Filed: July 5, 2006
    Date of Patent: May 6, 2008
    Assignee: Probiodrug AG
    Inventors: Stephan von Hoersten, Hans-Ulrich Demuth, Torsten Hoffmann
  • Patent number: 7335645
    Abstract: The invention relates to compounds for topically influencing the activity of dipeptidyl peptidase of the general formula wherein A is an amino acid having at least one functional group in the side chain; B is a chemical compound covalently bound to a functional group of the side chain of A, chosen from the group consisting of (a) oligopeptides having a chain length of up to 20 amino acids, (b) homopolymers of glycine consisting of up to 6 glycine monomers, and (c) polyethylene glycols having molar masses of up to 20 000 g/mol; and C is a group amide-bonded to A chosen from the group consisting of thiazolidine, pyrrolidine, cyanopyrrolidine, hydroxyproline, dehydroproline or piperidine.
    Type: Grant
    Filed: March 1, 2005
    Date of Patent: February 26, 2008
    Assignee: Probiodrug AG
    Inventors: Hans-Ulrich Demuth, Torsten Hoffmann, Dagmar Schlenzig, Ulrich Heiser
  • Publication number: 20070191366
    Abstract: The present invention provides novel physiological substrates of mammalian glutaminyl cyclase (QC, EC 2.3.2.5), new effectors of QC, methods for screening for such effectors, and the use of such effectors and pharmaceutical compositions comprising such effectors for the treatment of conditions that can be treated by modulation of QC-activity. Preferred compositions additionally comprise inhibitors of DP IV or DP IV-like enzymes for the treatment or alleviation of conditions that can be treated by modulation of QC- and DP IV-activity.
    Type: Application
    Filed: March 14, 2007
    Publication date: August 16, 2007
    Inventors: Torsten Hoffmann, Stephan Schilling, Andre Niestroj, Hans-Ulrich Demuth, Ulrich Heiser, Mirko Buchholz
  • Publication number: 20070129419
    Abstract: The present invention relates to cis-derivatives of formula wherein R1, R2, and R3 are as defined herein and to pharmaceutically acceptable acid addition salts thereof. The compounds of formula I are good inhibitors of the serotonin transporter (SERT inhibitors). By virtue of their efficacy as SERT inhibitors, the compounds of the present invention are particularly useful for the treatment of CNS disorders and psychotic disorders, in particular in the treatment or prevention of depressive states and/or in the treatment of anxiety.
    Type: Application
    Filed: November 22, 2006
    Publication date: June 7, 2007
    Inventors: Christophe Grundschober, Torsten Hoffmann, Andreas Koblet, Patrick Schnider
  • Patent number: 7211579
    Abstract: The present invention relates to compounds of formula I wherein R is methyl; and R1 is 4-methyl-4-oxy-piperazin-1-yl; or R is CH2OH and R1 is 4-methyl-piperazin-1-yl or is 4-methyl-4-oxy-piperazin-1-yl; and to pharmaceutically acceptable acid addition salts thereof for the treatment of NK-1 receptor related diseases, for example depression, Parkinson's disease, Alzheimer's disease, anxiety, emesis, and pain.
    Type: Grant
    Filed: March 15, 2006
    Date of Patent: May 1, 2007
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Christoph Funk, Torsten Hoffmann, Andreas Koblet
  • Patent number: 7176205
    Abstract: The present invention relates to compounds of the formula wherein R1 and R1? are each independently hydrogen or methyl and X is —C(O)N(CH3)— or —N(CH3)C(O)—, and to pharmaceutically acceptable acid addition salts thereof for the treatment of numerous inflammatory conditions, migraine, rheumatoid arthritis, asthma, inflammatory bowel disease, mediation of the emetic reflex, Parkinson's disease, anxiety, depression, psychosis, motion sickness, induced vomiting, pain, headache, migraine, Alzheimer's disease, multiple sclerosis, attenuation of morphine withdrawal, cardiovascular changes, oedema, such as oedema caused by thermal injury, chronic inflammatory diseases such as rheumatoid arthritis, asthma/bronchial hyperreactivity and other respiratory diseases including allergic rhinitis, inflammatory diseases of the gut including ulcerative colitis and Crohn's disease, ocular injury and ocular inflammatory diseases, traumatic brain injury, motion sickness, emesis and psychoimmunologic and psychosomatic disorder
    Type: Grant
    Filed: February 14, 2006
    Date of Patent: February 13, 2007
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Torsten Hoffmann, Patrick Schnider
  • Patent number: 7166579
    Abstract: Prodrug compounds of unstable inhibitors of the serine peptidase dipeptidyl peptidase IV, are used in the treatment of various disorders, especially of metabolic disorders. The Prodrug compounds can be used in the treatment of impaired glucose tolerance, glucosuria, hyperlipidaemia, metabolic acidoses, diabetes mellitus, diabetic neuropathy and nephropathy.
    Type: Grant
    Filed: December 11, 2003
    Date of Patent: January 23, 2007
    Assignee: Prosidion Limited
    Inventors: Hans-Ulrich Demuth, Dagmar Schlenzig, Torsten Hoffmann, Susanne Manhart
  • Patent number: 7160881
    Abstract: The present invention relates to a new crystalline modification of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-1?6-thiomorpholin-4-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide characterized by the following X-ray diffraction pattern obtained with a CuK?, radiation at 2? (2Theta)=4.5, 6.4, 7.5, 7.7, 8.0, 8.2, 10.0, 10.2, 10.9, 11.1, 12.9, 13.4, 14.0, 14.5, 15.1, 15.6, 16.2, 16.5, 17.3, 17.5, 18.0, 18.9, 19.3, 19.5, 19.9, 20.1, 20.6, 21.0, 21.4, 22.7, 23.1 and 23.6 and an infrared spectrum having sharp bands at 2925, 2854, 1637, 1604, 1484, 1395, 1375, 1285, 1230, 1172, 1125, 1082, 999, 943, 893, 868, 860, 782, 705, 684 cm?1, and wherein the extrapolated melting point (DSC) is 137.2° C.
    Type: Grant
    Filed: January 27, 2004
    Date of Patent: January 9, 2007
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Torsten Hoffmann, Fabienne Hoffmann-Emery, Sonja Nick, Urs Schwitter, Pius Waldmeier
  • Publication number: 20060293248
    Abstract: The present invention provides new uses of DPIV-inhibitors of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms, for treating conditions mediated by DPIV or DPIV-like enzymes, such as cancer and tumors. In a more preferred embodiment, the compounds of the present invention are useful for the treatment of metastasis and tumor colonization.
    Type: Application
    Filed: July 5, 2006
    Publication date: December 28, 2006
    Inventors: Stephen von Hoersten, Hans-Ulrich Demuth, Torsten Hoffmann
  • Publication number: 20060247240
    Abstract: The invention relates to a method of treatment and/or prevention of brain, spinal or nerve injury comprising administration to a person in need of such treatment, of a therapeutically effective amount of an NK-1 receptor antagonist compound of the formula wherein the meanings of R, R1, R2, R2, R3, and R4 are explained in the specification and the pharmaceutically acceptable acid addition salts and the prodrugs thereof either alone or in combination with a magnesium salt. Exemplified is the use of N-(3,5-bis-trifluoromethyl-benzyl)-N-methyl-6-(4-methyl-piperazin-1-yl)-4-o-tolyl-nicotinamide. The invention also relates to pharmaceutical composition comprising one or more such NK-1 receptor antagonists, optionally in combination with a magnesium salt, and a pharmaceutically acceptable excipient for the treatment and/or prevention of brain, spinal or nerve injury.
    Type: Application
    Filed: July 5, 2006
    Publication date: November 2, 2006
    Inventors: Torsten Hoffmann, Alan Nimmo, Andrew Sleight, Pierre Vankan, Robert Vink
  • Publication number: 20060217393
    Abstract: The present invention relates to compounds of formula I wherein R is methyl; and R1 is 4-methyl-4-oxy-piperazin-1-yl; or R is CH2OH and R1 is 4-methyl-piperazin-1-yl or is 4-methyl-4-oxy-piperazin-1-yl; and to pharmaceutically acceptable acid addition salts thereof for the treatment of NK-1 receptor related diseases, for example depression, Parkinson's disease, Alzheimer's disease, anxiety, emesis, and pain.
    Type: Application
    Filed: March 15, 2006
    Publication date: September 28, 2006
    Inventors: Christoph Funk, Torsten Hoffmann, Andreas Koblet
  • Publication number: 20060211729
    Abstract: Pharmaceutical compositions comprising an anticholinergic and at least one leukotriene inhibitor for treatment of respiratory diseases, including allergic rhinitis, bronchial asthma, COPD and common cold, and methods of treatment.
    Type: Application
    Filed: March 16, 2006
    Publication date: September 21, 2006
    Applicant: MEDA Pharma GmbH & Co. KG
    Inventors: Beatrix Fyrnys, Torsten Hoffmann, Mario Weingart, Istvan Szelenyi, Peter Cnota, Ullrich Munzel, Ursula Petzold, Joachim Maus
  • Patent number: 7109347
    Abstract: The present invention provides new uses of DPIV-inhibitors of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms, for treating conditions mediated by DPIV or DPIV-like enzymes, such as cancer and tumors. In a more preferred embodiment, the compounds of the present invention are useful for the treatment of metastasis and tumor colonization.
    Type: Grant
    Filed: March 30, 2005
    Date of Patent: September 19, 2006
    Assignee: Probiodrug AG
    Inventors: Stephan von Hoersten, Hans-Ulrich Demuth, Torsten Hoffmann
  • Publication number: 20060194852
    Abstract: The present invention provides compounds of the formula: wherein X?CH2 or S or pharmaceutical acceptable salts thereof useful for treating conditions mediated by DPIV or DPIV-like enzymes, such as arthritis, obesity, immune and autoimmune disorders, allograft transplantation, cancer, neuronal disorders and dermal diseases.
    Type: Application
    Filed: March 7, 2006
    Publication date: August 31, 2006
    Inventors: Hans-Ulrich Demuth, Torsten Hoffmann, Ulrich Heiser
  • Publication number: 20060189626
    Abstract: The present invention relates to compounds of the formula wherein R1 and R1? are each independently hydrogen or methyl and X is —C(O)N(CH3)— or —N(CH3)C(O)—, and to pharmaceutically acceptable acid addition salts thereof for the treatment of numerous inflammatory conditions, migraine, rheumatoid arthritis, asthma, inflammatory bowel disease, mediation of the emetic reflex, Parkinson's disease, anxiety, depression, psychosis, motion sickness, induced vomiting, pain, headache, migraine, Alzheimer's disease, multiple sclerosis, attenuation of morphine withdrawal, cardiovascular changes, oedema, such as oedema caused by thermal injury, chronic inflammatory diseases such as rheumatoid arthritis, asthma/bronchial hyperreactivity and other respiratory diseases including allergic rhinitis, inflammatory diseases of the gut including ulcerative colitis and Crohn's disease, ocular injury and ocular inflammatory diseases, traumatic brain injury, motion sickness, emesis and psychoimmunologic and psychosomatic disorde
    Type: Application
    Filed: February 14, 2006
    Publication date: August 24, 2006
    Inventors: Torsten Hoffmann, Patrick Schnider